Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial

Eich, Hans Theodor; Diehl, Volker; Görgen, Helen; Pabst, Thomas; Markova, Jana; Debus, Jürgen; Ho, Anthony; Dörken, Bernd; Rank, Andreas; Grosu, Anca-Ligia; Wiegel, Thomas; Karstens, Johann Hinrich; Greil, Richard; Willich, Normann; Schmidberger, Heinz; Döhner, Hartmut; Borchmann, Peter; Müller-Hermelink, Hans-Konrad; Müller, Rolf-Peter and Engert, Andreas (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of clinical oncology, 28(27), pp. 4199-206. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.29.8018

Full text not available from this repository. (Request a copy)

Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1200/JCO.2010.29.8018

PubMed ID:

20713848

Web of Science ID:

000281909700016

URI:

https://boris.unibe.ch/id/eprint/1084 (FactScience: 201831)

Actions (login required)

Edit item Edit item
Provide Feedback